Results 291 to 300 of about 344,150 (327)

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

American Journal of Hematology, EarlyView.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia‐Manero, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Anita K. Gandhi, Rajasekhar N. V. S. Suragani   +9 more
wiley   +1 more source

Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response. [PDF]

Nucleic Acids Res
Xiong J, Bricard O, Arijs I, Demeulemeester J, Gu C, Thienpont B, Daaboul D, Bassez A, Bechter O, Poźniak J, Vos H, Nevelsteen I, Torfs S, Santos SA, Lan Q, Hou Y, Van Oudenhove L, Boons G, Qian J, Aerts S, Smeets A, Marine JC, Lambrechts D.   +22 more
europepmc   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source

Age-related aberrant alternative splicing as a prognostic tool in older breast cancer patients. [PDF]

Commun Biol
Chen M, Xiao T, Ke H, Ye C, Yu F, Su J, Yang S, Feng Y, Xu H, Fu S, Lin L, Lin J, Xie Y, Ding Q, Qiu Y, Yu R, Lv H, Li W, Zhang Y, Ding Z, Zou Y, Yuan H, Zhao L.   +22 more
europepmc   +1 more source

Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin (EPO) Due to EPO c.‐136 G>A Germline Mutation

American Journal of Hematology, EarlyView.
A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova, Dusan Hrckulak, Veronika Zimolova, Felipe R. Lorenzo, Jihyun Song, Katerina Vecerkova, Olga Babosova, Linda Berkova, Vladimir Korinek, Steve Elliott, Josef T. Prchal   +10 more
wiley   +1 more source

Aberrant alternative splicing in alcoholic hepatitis: regulatory roles of RBPs and sQTLs. [PDF]

BMC Gastroenterol
Zhao J, Cheng J, Liang S, Guo W, Zhao B, Zhang H, Mei X, Zhang N, Sheng M.   +8 more
europepmc   +1 more source

ZC3H18 regulates alternative splicing and related genes in cervical cancer. [PDF]

Front Genet
Chen W, Liu C, Li S, Xie X, Hu D, Lin Y.
europepmc   +1 more source

Alternative Splicing Regulation in Metabolic Disorders. [PDF]

Obes Rev
Kaminska D.
europepmc   +1 more source

Alternative Splicing of SORBS1 Affects Neuromuscular Junction Integrity in Myotonic Dystrophy Type 1. [PDF]

J Cachexia Sarcopenia Muscle
Hermitte C, de Calbiac H, Moulay G, Mérien A, Lainé J, Polvèche H, Cailleret M, Vassilopoulos S, Kabashi E, Furling D, Martinat C, Gazzola M.   +11 more
europepmc   +1 more source